The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.
about
Medical healthcare use in Parkinson's disease: survey in a cohort of ambulatory patients in ItalySocietal costs of exposure to toxic substances: economic and health costs of four case studies that are candidates for environmental causationDeep Brain Stimulation for Parkinson's Disease with Early Motor Complications: A UK Cost-Effectiveness AnalysisCost effectiveness of preventing falls and improving mobility in people with Parkinson disease: protocol for an economic evaluation alongside a clinical trialQuantifying the profile and progression of impairments, activity, participation, and quality of life in people with Parkinson disease: protocol for a prospective cohort study.Treatment of Parkinson's disease should begin with a dopamine agonist.A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III).Cost-effectiveness analysis in Parkinson's disease: determining the value of interventions.Do neurologists in Germany adhere to the national Parkinson's disease guideline?Pharmacotherapy in the management of early Parkinson's disease: cost-effectiveness and patient acceptability.Measuring the Burden of Hospitalization in Patients with Parkinson´s Disease in Spain.The effect of deep brain stimulation on quality of life in movement disorders.Levodopa, motor fluctuations and dyskinesia in Parkinson's disease.A Patient-Based Needs Assessment for Living Well with Parkinson Disease: Implementation via Nominal Group Technique.Costs of Parkinson's disease in a privately insured population.Modelling the cost effectiveness of treatments for Parkinson's disease: a methodological review.Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease.Emerging drugs for levodopa-induced dyskinesia.Impaired intracellular trafficking defines early Parkinson's diseaseDrug and treatment costs in Parkinson's disease patients in Sweden.[Dementia and depression determine care dependency in Parkinson's disease: analysis of 1,449 outpatients receiving nursing care in Germany].Cabergoline versus levodopa monotherapy: a decision analysis.Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease.Longitudinal study of the socioeconomic burden of Parkinson's disease in Germany.A review of physiological and behavioral monitoring with digital sensors for neuropsychiatric illnesses.Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
P2860
Q24793543-57C691AD-D907-4370-82C2-573FD68EAFF4Q24814856-87B635F1-2F03-45E7-B7A4-BE750E21A784Q26779605-9E6844F4-A44A-45B3-9F51-124F65ADACD8Q33372608-9A2B56B6-8C4B-4B8F-82EE-E36518648FFEQ33400886-7BD21699-0F8D-4BB7-A999-AF84D112C0F8Q33737392-D57296FA-B626-4726-9A46-C1361FB97C0CQ33753874-30888081-7E94-468C-AEE0-67C1389CFC75Q33929699-F50DEC32-B73B-404D-A6BA-11B562B4DF41Q34879044-FC84F96B-B064-40F2-9B30-98D522DE50FBQ35205344-30F33680-4F9A-4B46-A6BF-89A407A3C89BQ35957508-58F25E5A-063F-4F2A-9631-E42A36B0BDDBQ36233666-F550F74E-A52C-46A6-86C9-8FC6EC71C23BQ36573882-D0FE8669-04DA-4705-BEAF-D4A82A739D8FQ36656468-9F79A32B-4BF8-4D15-9544-81B410C92335Q37132304-03B81F64-0C6C-425F-A201-17188EF51486Q37955238-5BCE60E5-F8CD-4E12-ACF6-F2AFE6EF7922Q38122127-71DA2FF3-37CD-484A-8BAE-D17E081E5298Q38242091-EA07D010-81CC-4351-B2F5-FBE3904C494DQ38256380-A71835C9-E817-4A75-A74C-D63A51BE9611Q39763335-565073E7-17D9-4C8A-8BB1-3354A2A0BC9CQ44056635-3FE57324-634F-44B9-A0FA-07584CA3D44BQ44531222-D10020ED-29E8-4663-9C22-B37712867C9FQ48583756-B5B63C21-D77A-4E1F-A62D-443CB2D5E078Q51143314-691B8126-08F7-4C82-8208-F8498A38ECA7Q53407108-CAEB0BCF-888A-4706-96DE-101C00799708Q53930312-F5A5AFE4-1E36-4BF4-84B2-3A62A5ADF3D0
P2860
The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
The economic impact of Parkins ...... 3-month prospective analysis.
@en
type
label
The economic impact of Parkins ...... 3-month prospective analysis.
@en
altLabel
The Economic Impact of Parkinson???s Disease
@en
prefLabel
The economic impact of Parkins ...... 3-month prospective analysis.
@en
P2093
P1433
P1476
The economic impact of Parkins ...... 3-month prospective analysis.
@en
P2093
P304
P356
10.2165/00019053-199814030-00006
P577
1998-09-01T00:00:00Z
P6179
1010757912